Bexarotene has been proved to have
neuroprotective effects in many animal models of neurological diseases. However, its neuroprotection in
traumatic brain injury (TBI) is still unknown. This study aims to explore the
neuroprotective effects of
bexarotene on TBI and its possible mechanism. Controlled cortical impact (CCI) model was used to simulate TBI in C57BL/6 mice as well as
APOE gene knockout (
APOE-KO) mice. After CCI, mice were daily dosed with
bexarotene or vehicle
solution intraperitoneally. The motor function, learning and memory, inflammatory factors, microglia amount, apoptosis condition around injury site and main side-effects were all measured. The results showed that, after CCI,
bexarotene treatment markedly improved the motor function and spatial memory in C57BL/6 compare to
APOE-KO mice which showed no improvement. The inflammatory
cytokines, microglia amount, cell apoptosis rate, and
protein of cleaved
caspase-3 around the injury site were markedly upregulated after TBI in both C57BL/6 and
APOE-KO mice, and all these upregulation were significantly mitigated by
bexarotene treatment in C57BL/6 mice, but not in
APOE-KO mice. No side-effects were detected after consecutive administration. Taken together,
bexarotene inhibits the inflammatory response as well as cell apoptosis and improves the neurological function of mice after TBI partially through
apolipoprotein E. This may make it a promising candidate for the therapeutic treatment after TBI.